Trial Profile
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Hydrocortisone; Mercaptopurine; Methotrexate; Mitoxantrone; Pegaspargase; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; Onyx Pharmaceuticals
- 15 Apr 2024 Planned End Date changed from 4 Aug 2024 to 14 Jul 2024.
- 15 Apr 2024 Planned primary completion date changed from 14 May 2024 to 14 Jul 2024.
- 15 Apr 2024 Status changed from recruiting to active, no longer recruiting.